A phase 1 clinical trial showed that a combination of ALT-803 (an IL-15 superagonist) and nivolumab (monoclonal antibody of PD-1) in non-small cell lung cancer (NSCLC) was safe and showed remarkable response rate, especially in PD-L1-positive patients (40). Here, IL15 is linked to non-small cell lung carcinoma.